Russell Investments Group Ltd. grew its position in Becton, Dickinson and Company (NYSE:BDX) by 1.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 814,791 shares of the medical instruments supplier’s stock after buying an additional 8,621 shares during the quarter. Russell Investments Group Ltd. owned 0.36% of Becton, Dickinson and worth $159,628,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of the business. Vanguard Group Inc. lifted its holdings in shares of Becton, Dickinson and by 8.5% in the 2nd quarter. Vanguard Group Inc. now owns 17,255,948 shares of the medical instruments supplier’s stock worth $3,366,809,000 after buying an additional 1,353,780 shares during the period. BlackRock Inc. lifted its holdings in shares of Becton, Dickinson and by 2,427.8% in the 1st quarter. BlackRock Inc. now owns 16,542,028 shares of the medical instruments supplier’s stock worth $3,034,470,000 after buying an additional 15,887,611 shares during the period. State Street Corp raised its position in shares of Becton, Dickinson and by 3.5% in the 2nd quarter. State Street Corp now owns 10,270,221 shares of the medical instruments supplier’s stock worth $2,003,834,000 after acquiring an additional 342,873 shares in the last quarter. Northern Trust Corp raised its position in shares of Becton, Dickinson and by 4.0% in the 2nd quarter. Northern Trust Corp now owns 2,813,937 shares of the medical instruments supplier’s stock worth $549,028,000 after acquiring an additional 106,966 shares in the last quarter. Finally, Fiera Capital Corp raised its position in shares of Becton, Dickinson and by 7.1% in the 2nd quarter. Fiera Capital Corp now owns 2,782,146 shares of the medical instruments supplier’s stock worth $542,825,000 after acquiring an additional 183,372 shares in the last quarter. Institutional investors and hedge funds own 86.01% of the company’s stock.

Shares of Becton, Dickinson and Company (NYSE:BDX) traded down $1.21 during trading hours on Friday, reaching $220.31. The company had a trading volume of 718,967 shares, compared to its average volume of 1,325,275. Becton, Dickinson and Company has a 12 month low of $161.29 and a 12 month high of $225.23. The firm has a market cap of $50,410.00, a price-to-earnings ratio of 23.23, a P/E/G ratio of 1.73 and a beta of 1.04. The company has a quick ratio of 5.01, a current ratio of 5.56 and a debt-to-equity ratio of 1.48.

Becton, Dickinson and (NYSE:BDX) last announced its earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.37 by $0.03. Becton, Dickinson and had a return on equity of 22.51% and a net margin of 8.52%. The company had revenue of $3.17 billion for the quarter, compared to analyst estimates of $3.14 billion. During the same period in the prior year, the company posted $2.12 EPS. The firm’s quarterly revenue was down 2.0% compared to the same quarter last year. equities analysts predict that Becton, Dickinson and Company will post 10.63 earnings per share for the current fiscal year.

In other news, insider Gary M. Cohen sold 15,044 shares of the stock in a transaction dated Tuesday, August 22nd. The stock was sold at an average price of $200.43, for a total value of $3,015,268.92. Following the transaction, the insider now directly owns 95,270 shares of the company’s stock, valued at $19,094,966.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Linda M. Tharby sold 4,695 shares of the stock in a transaction dated Tuesday, August 22nd. The shares were sold at an average price of $200.48, for a total value of $941,253.60. Following the completion of the transaction, the executive vice president now directly owns 18,670 shares in the company, valued at $3,742,961.60. The disclosure for this sale can be found here. Insiders have sold a total of 47,038 shares of company stock worth $9,480,225 over the last ninety days. 1.40% of the stock is currently owned by corporate insiders.

WARNING: This news story was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another publication, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/11/18/russell-investments-group-ltd-raises-holdings-in-becton-dickinson-and-company-bdx.html.

Several research analysts have recently commented on BDX shares. Piper Jaffray Companies reissued a “buy” rating and issued a $213.00 price target on shares of Becton, Dickinson and in a research report on Tuesday, September 12th. Zacks Investment Research lowered Becton, Dickinson and from a “hold” rating to a “sell” rating in a research report on Monday, October 9th. Royal Bank Of Canada reissued a “hold” rating and issued a $210.00 price target on shares of Becton, Dickinson and in a research report on Wednesday, October 25th. Wells Fargo & Company started coverage on Becton, Dickinson and in a research report on Friday, September 22nd. They issued an “outperform” rating and a $225.00 price target for the company. Finally, Bank of America Corporation reissued a “buy” rating and issued a $225.00 price target (up from $200.00) on shares of Becton, Dickinson and in a research report on Friday, July 21st. Five analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. Becton, Dickinson and has an average rating of “Buy” and a consensus price target of $213.47.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Stock Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related stocks with our FREE daily email newsletter.